AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer

This is a prospective, open-label, single arm clinical study. The main purpose of the study is to evaluate the clinical efficacy and safety of nab-paclitaxel/gemcitabine combined with nimotuzumab sequential irreversible electroporation ablation for locally advanced pancreatic cancer. The main endpoint is overall survival (OS).

NCT Number	NCT06938503
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital
Conditions	Pancreatic Cancer, Adult
Enrollment	48 participants
Start Date	2025-04-21
Primary Completion	2028-04-25 (estimated)
Study Completion	2028-04-28 (estimated)
Updated on ClinicalTrials.gov	2025-04-22